ANURAS vs TATVA: Stock Comparison

Anupam Rasayan India Limited vs Tatva Chintan Pharma Chem Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Anupam Rasayan India Limited is the larger company by market capitalisation. Anupam Rasayan India Limited shows a higher dividend yield, faster revenue growth and lower leverage, while Tatva Chintan Pharma Chem Limited shows a lower P/E and a higher ROE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Anupam Rasayan India Limited and Tatva Chintan Pharma Chem Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ANURAS is more favourable on 8 of 13 scored metrics and TATVA on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ANURAS is the larger company
₹14,231 Cr vs ₹4,033 Cr
P/E Ratio
TATVA has a lower P/E
78.3x vs 82.46x
P/B Ratio
ANURAS has a lower P/B
4.21x vs 5.15x
EPS
TATVA has higher earnings per share
₹18.84 vs ₹15.45
Dividend Yield
ANURAS has a higher dividend yield
0.12% vs 0.08%
Revenue Growth (TTM YoY)
ANURAS has faster revenue growth
27.5% vs 24.4%
EPS Growth (TTM YoY)
TATVA has faster EPS growth
907.5% vs -7.6%
Qtr Sales Growth
ANURAS has stronger quarterly sales growth
27.1% vs 24.4%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricANURASTATVA
SectorChemicalsChemicals
IndustrySpecialty ChemicalsSpecialty Chemicals

Price

MetricANURASTATVA
Live Price₹1,249.6₹1,722.4
Day Change0.85%1.27%
Volume2.82 L1.56 L
52-Week High₹1,415₹1,785
52-Week Low₹1,045.2₹976.4
Distance from 52W High-11.69%-3.51%

Valuation

MetricANURASTATVA
Market Cap₹14,231 Cr₹4,033 Cr
P/E Ratio82.46x78.3x
P/B Ratio4.21x5.15x
EPS₹15.45₹18.84
Book Value₹293.12₹334.03
Dividend Yield0.12%0.08%

Growth

MetricANURASTATVA
Revenue Growth (TTM YoY)27.5%24.4%
EPS Growth (TTM YoY)-7.6%907.5%
Qtr Sales Growth27.1%24.4%
Qtr Profit Growth-4.31%902%

Profitability & Leverage

MetricANURASTATVA
ROE5.5%5.53%
ROCE7.36%7.14%
Net Margin8.41%8.31%
Operating Margin22.2%11.13%
Debt to Equity0.56x15.4x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricANURASTATVA
Promoter Holding27.27%72.02%
FII Holding7.71% 0.8 pp3.93% 0.11 pp
DII Holding0.38% 0.03 pp3.11% 0.12 pp
Public Holding32.83% 0.84 pp20.94% 0.23 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Anupam Rasayan India Limited and Tatva Chintan Pharma Chem Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.